Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-κB

Abstract

Epstein-Barr virus (EBV) transforms resting primary human B lymphocytes into indefinitely proliferating lymphoblastoid cell lines in vitro and is associated with several human malignancies in vivo. Recombinant EBV genetic analyses combined with in vitro B lymphocyte transformation assays demonstrate that latent infection membrane protein 1 (LMP1) is essential for EBV-mediated lymphocyte transformation. LMP1 has no intrinsic enzymatic activity but instead aggregates cellular proteins of the tumor necrosis factor receptor signaling pathway to activate transcription factor NF-κB. Mutants rendering LMP1 defective in these protein interactions are impaired in their abilities to activate NF-κB in reporter gene assays. Concordantly, EBV recombinants with LMP1 mutations that are compromised for NF-κB activation are impaired for growth transformation. Thus, EBV-mediated growth transformation is genetically and biochemically linked to LMP1-mediated activation of NF-κB.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  • Asso-Bonnet M, Feuillard J, Ferreira V, Bissieres P, Tarantino N, Korner M and Raphael M. . 1998 Oncogene 17: 1607–1615.

  • Babcock GJ, Decker LL, Volk M and Thorley-Lawson DA. . 1998 Immunity 9: 395–404.

  • Baichwal VR and Sugden B. . 1988 Oncogene 2: 461–467.

  • Banchereau J, de Paoli P, Valle A, Garcia E and Rousset F. . 1991 Science 251: 70–72.

  • Barkett M and Gilmore TD. . 1999 Oncogene 18: 6910–6924.

  • Brodeur SR, Cheng G, Baltimore D and Thorley-Lawson DA. . 1997 J. Biol. Chem. 272: 19777–19784.

  • Busch LK and Bishop GA. . 1999 J. Immunol. 162: 2555–2561.

  • Cohen JI, Wang F, Mannick J and Kieff E. . 1989 Proc. Natl. Acad. Sci. USA 86: 9558–9562.

  • Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF and Kieff E. . 1998 J. Virol. 72: 7900–7908.

  • Devergne O, Hatzivassiliou E, Izumi KM, Kaye KM, Kleijnen MF, Kieff E and Mosialos G. . 1996 Mol. Cell. Biol. 16: 7098–7108.

  • Eliopoulos AG, Blake SM, Floettmann JE, Rowe M and Young LS. . 1999a J. Virol. 73: 1023–1035.

  • Eliopoulos AG, Dawson CW, Mosialos G, Floettmann JE, Rowe M, Armitage RJ, Dawson J, Zapata JM, Kerr DJ, Wakelam MJ, Reed JC, Kieff E and Young LS. . 1996 Oncogene 13: 2243–2254.

  • Eliopoulos AG, Gallagher NJ, Blake SM, Dawson CW and Young LS. . 1999b J. Biol. Chem. 274: 16085–16096.

  • Eliopoulos AG and Young LS. . 1998 Oncogene 16: 1731–1742.

  • Epstein MA, Achong BG and Pope JH. . 1967 Br. Med. J. 2: 290–291.

  • Fennewald S, van Santen V and Kieff E. . 1984 J. Virol. 51: 411–419.

  • Finke J, Fritzen R, Ternes P, Trivedi P, Bross KJ, Lange W, Mertelsmann R and Dolken G. . 1992 Blood 80: 459–469.

  • Floettmann JE and Rowe M. . 1997 Oncogene 15: 1851–1858.

  • Franken M, Devergne O, Rosenzweig M, Annis B, Kieff E and Wang F. . 1996 J. Virol. 70: 7819–7826.

  • Fries KL, Miller WE and Raab-Traub N. . 1996 J. Virol. 70: 8653–8659.

  • Gires O, Kohlhuber F, Kilger E, Baumann M, Kieser A, Kaiser C, Zeidler R, Scheffer B, Ueffing M and Hammerschmidt W. . 1999 EMBO J. 18: 3064–3073.

  • Gires O, Zimber-Strobl U, Gonnella R, Ueffing M, Marschall G, Zeidler R, Pich D and Hammerschmidt W. . 1997 EMBO J. 16: 6131–6140.

  • Hamilton-Dutoit SJ, Delecluse HJ, Raphael M, Lenoir G and Pallesen G. . 1991 J. Clin. Pathol. 44: 676–680.

  • Hamilton-Dutoit SJ, Rea D, Raphael M, Sandvej K, Delecluse HJ, Gisselbrecht C, Marelle L, van Krieken HJ and Pallesen G. . 1993 Am. J. Pathol. 143: 1072–1085.

  • Hammerschmidt W and Sugden B. . 1989 Nature 340: 393–397.

  • Hatzivassiliou E, Miller WE, Raab-Traub N, Kieff E and Mosialos G. . 1998 J. Immunol. 160: 1116–1121.

  • Heller M, van Santen V and Kieff E. . 1982 J. Virol. 44: 311–320.

  • Henderson S, Rowe M, Gregory C, Croom-Carter D, Wang F, Longnecker R, Kieff E and Rickinson A. . 1991 Cell 65: 1107–1115.

  • Henle G, Henle W, Clifford P, Diehl V, Kafuko GW, Kirya BG, Klein G, Morrow RH, Munube GM, Pike P, Tukei PM and Ziegler JL. . 1969 J. Natl. Cancer Inst. 43: 1147–1157.

  • Henle G, Henle W and Diehl V. . 1968 Proc. Natl. Acad. Sci. USA 59: 94–101.

  • Henle W, Diehl V, Kohn G, Zur Hausen H and Henle G. . 1967 Science 157: 1064–1065.

  • Henle W and Henle G. . 1970 Bibl. Haematol. 36: 706–713.

  • Henle W, Henle G and Lennette ET. . 1979 Sci. Am. 241: 48–59.

  • Hennessy K, Fennewald S, Hummel M, Cole T and Kieff E. . 1984 Proc. Natl. Acad. Sci. USA 81: 7207–7211.

  • Hennessy K, Fennewald S and Kieff E. . 1985 Proc. Natl. Acad. Sci. USA 82: 5944–5948.

  • Hennessy K, Heller M, van Santen V and Kieff E. . 1983 Science 220: 1396–1398.

  • Hennessy K and Kieff E. . 1985 Science 227: 1238–1240.

  • Hennessy K, Wang F, Bushman EW and Kieff E. . 1986 Proc. Natl. Acad. Sci. USA 83: 5693–5697.

  • Ho M, Miller G, Atchison RW, Breinig MK, Dummer JS, Andiman W, Starzl TE, Eastman R, Griffith BP, Hardesty RL, Bahnson HT, Hakala TR and Rosenthal JT. . 1985 J. Infect. Dis. 152: 876–886.

  • Huen DS, Henderson SA, Croom-Carter D and Rowe M. . 1995 Oncogene 10: 549–560.

  • Izuhara K, Heike T, Otsuka T, Yamaoka K, Mayumi M, Imamura T, Niho Y and Harada N. . 1996 J. Biol. Chem. 271: 619–622.

  • Izumi KM, Cahir McFarland ED, Ting AT, Riley EA, Seed B and Kieff ED. . 1999 Mol. Cell. Biol. 19: 5759–5767.

  • Izumi KM, Kaye KM and Kieff ED. . 1994 J. Virol. 68: 4369–4376.

  • Izumi KM, Kaye KM and Kieff ED. . 1997 Proc. Natl. Acad. Sci. USA 94: 1447–1452.

  • Izumi KM and Kieff ED. . 1997 Proc. Natl. Acad. Sci. USA 94: 12592–12597.

  • Karin M. . 1999 Oncogene 18: 6867–6874.

  • Kawanishi M. . 1997 Virology 228: 244–250.

  • Kaye KM, Devergne O, Harada JN, Izumi KM, Yalamanchili R, Kieff E and Mosialos G. . 1996 Proc. Natl. Acad. Sci. USA 93: 11085–11090.

  • Kaye KM, Izumi KM and Kieff E. . 1993 Proc. Natl. Acad. Sci. USA 90: 9150–9154.

  • Kaye KM, Izumi KM, Mosialos G and Kieff E. . 1995 J. Virol. 69: 675–683.

  • Kelliher MA, Grimm S, Ishida Y, Kuo F, Stanger BZ and Leder P. . 1998 Immunity 8: 297–303.

  • Kenney JL, Guinness ME, Curiel T and Lacy J. . 1998 Blood 92: 1721–1727.

  • Kieser A, Kilger E, Gires O, Ueffing M, Kolch W and Hammerschmidt W. . 1997 EMBO J. 16: 6478–6485.

  • Kilger E, Kieser A, Baumann M and Hammerschmidt W. . 1998 EMBO J. 17: 1700–1709.

  • Laherty CD, Hu HM, Opipari AW, Wang F and Dixit VM. . 1992 J. Biol. Chem. 267: 24157–24160.

  • Lang DJ, Garruto RM and Gajdusek DC. . 1977 Am. J. Epidemiol. 105: 480–487.

  • Lee MA, Diamond ME and Yates JL. . 1999 J. Virol. 73: 2974–2982.

  • Liebowitz D, Wang D and Kieff E. . 1986 J. Virol. 58: 233–237.

  • Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J and MacLennan IC. . 1989 Nature 342: 929–931.

  • Longnecker R and Kieff E. . 1990 J. Virol. 64: 2319–2326.

  • Longnecker R, Miller CL, Miao XQ, Tomkinson B and Kieff E. . 1993 J. Virol. 67: 2006–2013.

  • Macchi P, Villa A, Gillani S, Sacco MG, Frattini A, Porta F, Ugazio AG, Johnston JA, Candotti F, O'Shea JJ, Johnston JA, Candotti F, O'Shea JJ, Vezzoni P and Notarangelo LD. . 1995 Nature 377: 65–68.

  • MacMahon EM, Glass JD, Hayward SD, Mann RB, Becker PS, Charache P, McArthur JC and Ambinder RF. . 1991 Lancet 338: 969–973.

  • Mann KP and Thorley-Lawson D. . 1987 J. Virol. 61: 2100–2108.

  • Mannick JB, Cohen JI, Birkenbach M, Marchini A and Kieff E. . 1991 J. Virol. 65: 6826–6837.

  • Miller WE, Mosialos G, Kieff E and Raab-Traub N. . 1997 J. Virol. 71: 586–594.

  • Mitchell T and Sugden B. . 1995 J. Virol. 69: 2968–2976.

  • Moorthy RK and Thorley-Lawson DA. . 1993a J. Virol. 67: 1638–1646.

  • Moorthy RK and Thorley-Lawson DA. . 1993b J. Virol. 67: 2637–2645.

  • Mosialos G, Birkenbach M, Yalamanchili R, VanArsdale T, Ware C and Kieff E. . 1995 Cell 80: 389–399.

  • Niedobitek G, Hansmann ML, Herbst H, Young LS, Dienemann D, Hartmann CA, Finn T, Pitteroff S, Welt A, Anagnostopoulos I, Friedrich R, Lobeck H, Sam CK, Araujo I, Rickinson AB and Stein H. . 1991 J. Pathol. 165: 17–24.

  • Nilsson K, Klein G, Henle W and Henle G. . 1971 Int. J. Cancer 8: 443–450.

  • Pope JH, Horne MK and Scott W. . 1968 Int. J. Cancer 3: 857–866.

  • Pope JH, Horne MK and Scott W. . 1969 Int. J. Cancer 4: 255–260.

  • Rickinson AB, Epstein MA and Crawford DH. . 1975 Nature 258: 236.

  • Rickinson AB and Kieff E. . 1996 In: Fields Virology. Fields BN, Knipe DM and Howley PM. (eds).. Lippincott-Raven Publishers: Philadelphia pp. 2397–2446.

    Google Scholar 

  • Rickinson AB, Moss DJ, Pope JH and Ahlberg N. . 1980 Int. J. Cancer 25: 59–65.

  • Robertson ES, Tomkinson B and Kieff E. . 1994 J. Virol. 68: 1449–1458.

  • Rothe M, Sarma V, Dixit VM and Goeddel DV. . 1995 Science 269: 1424–1427.

  • Russell SM, Tayebi N, Nakajima H, Riedy MC, Roberts JL, Aman MJ, Migone TS, Noguchi M, Markert ML, Buckley RH, O'Shea JJ and Leonard WJ. . 1995 Science 270: 797–800.

  • Sandberg M, Hammerschmidt W and Sugden B. . 1997 J. Virol. 71: 4649–4656.

  • Sarma V, Lin Z, Clark L, Rust BM, Tewari M, Noelle RJ and Dixit VM. . 1995 J. Biol. Chem. 270: 12343–12346.

  • Shibata D and Weiss LM. . 1992 Am. J. Pathol. 140: 769–774.

  • Smith PR, Gao Y, Karran L, Jones MD, Snudden D and Griffin BE. . 1993 J. Virol. 67: 3217–3225.

  • Sun S-C and Ballard DW. . 1999 Oncogene 18: 6948–6958.

  • Swaminathan S, Tomkinson B and Kieff E. . 1991 Proc. Natl. Acad. Sci. USA 88: 1546–1550.

  • Sylla BS, Hung SC, Davidson DM, Hatzivassiliou E, Malinin NL, Wallach D, Gilmore TD, Kieff E and Mosialos G. . 1998 Proc. Natl. Acad. Sci. USA 95: 10106–10111.

  • Ting AT, Pimentel-Muinos FX and Seed B. . 1996 EMBO J. 15: 6189–6196.

  • Tomkinson B and Kieff E. . 1992 J. Virol. 66: 2893–2903.

  • Tomkinson B, Robertson E and Kieff E. . 1993 J. Virol. 67: 2014–2025.

  • Wang CY, Mayo MW, Korneluk RG, Goeddel DV and Baldwin Jr AS. . 1998 Science 281: 1680–1683.

  • Wang D, Liebowitz D and Kieff E. . 1985 Cell 43: 831–840.

  • Weiss LM, Strickler JG, Warnke RA, Purtilo DT and Sklar J. . 1987 Am. J. Pathol. 129: 86–91.

  • Yao QY, Ogan P, Rowe M, Wood M and Rickinson AB. . 1989 Int. J. Cancer 43: 67–71.

  • Zimber-Strobl U, Kempkes B, Marschall G, Zeidler R, Van Kooten C, Banchereau J, Bornkamm GW and Hammerschmidt W. . 1996 EMBO J. 15: 7070–7078.

Download references

Acknowledgements

We thank Elliott Kieff for his support, and we also thank Stephanine Schauer, Kara Carter and Jimmy Duong for comments on the manuscript. ED Cahir McFarland, KM Izumi, and G Mosialos are supported by the US Public Health Service grants CA76727, CA47006, and CA71705, respectively.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

McFarland, E., Izumi, K. & Mosialos, G. Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-κB. Oncogene 18, 6959–6964 (1999). https://doi.org/10.1038/sj.onc.1203217

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1203217

Keywords

This article is cited by

Search

Quick links